Targeted nucleic acids can interfere with cell proliferation, angiogenesis, metastasis, chemotherapy resistance, etc., and have broad prospects for drug development. CD BioSciences provides comprehensive peptidomimetic development services for targeted nucleic acids to help advance untargeted diseases.
Overview of Nucleic Acids
Nucleic acids, including DNA and RNA, are living substances that direct protein synthesis and control cell division. Interfering or blocking the synthesis of nucleic acid, the basic substance for the proliferation of bacteria, viruses and tumor cells, can effectively kill or inhibit bacteria, pathogens and tumor cells.
Advantages of Targeting RNA
Fig. 1 RNA is highly structured.
(Meyer S M, et al., 2020)
Due to the existence of various forms of RNA in the human body, in addition to messenger RNA (mRNA) that can be expressed as protein, there are also various non-coding RNA (ncRNA), which are involved in a series of physiological activities that affect human function and health, such as gene expression, regulation, and protein translation. In addition, RNA can form diverse and complex structures that are altered by RNA mutations, resulting in loss of normal or abnormal functioning of the organism, both of which are closely related to a variety of diseases.
Requirements for Targeting RNA
- Need to find disease-related RNA targets
- Find small molecules that can bind to RNA through high-throughput screening
- Target small molecules can bind to RNA with high affinity and high specificity
Existing small molecule binding RNA screening methods include high-throughput screening, structure-inspired design, fragment-based screening methods, and in silico modeling. Some binding-based high-throughput screening methods are shown in Fig.2.
Fig. 2 Some common screening methods used to detect RNA-small molecule binding. (Falese J P, et al., 2021)
Our Services
Small-molecule nucleic acid-targeted drugs developed to meet the above conditions still have many limitations, such as low bioavailability and short in vivo half-life after entering the human body. Based on this, peptidomimetics developed with our PepDomTM are able to solve the above problems. Using this platform's high-throughput screening technology and structure modification technology, peptidomimetics with smaller molecular weight and stronger affinity can be developed.
CD BioSciences is dedicated to providing a variety of nucleic acid-targeting peptidomimetics development services. Our services include but are not limited to:
RNA Target-Based Peptidomimetic Development Service
- mRNA-related targets
- Non-coding RNAs: rRNA, tRNA, snRNA, snoRNA, miRNA, etc.
DNA Target-Based Peptidomimetic Development Service
- DNA repair damage-related pathways
- Mitochondrial DNA-protein interactions
- Other related targets
Features of Our Service
We are committed to helping customers achieve better research progress in the field of nucleic acid-targeting peptidomimetic drug development.
Customer First
Highly Customizable
Rapid Turnaround
High Quality
In addition to the development of targets provided by customers, we are also able to explore potential targets according to the needs of customers. As long as you are interested, you can contact us for our professional advice and solutions.
References
- Meyer, S. M., Williams, C. C., Akahori, Y., et al. (2020). Small molecule recognition of disease-relevant rna structures. Chemical Society Reviews, 49(19):7167-7199.
- Falese, J. P., Donlic, A., & Hargrove, A. E. (2021). Targeting RNA with small molecules: from fundamental principles towards the clinic. Chemical Society Reviews, 50(4):2224-2243.
- Walker, M. J., & Varani, G. (2019). Design of RNA-targeting macrocyclic peptides. Methods in Enzymology. 623:339-372.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
